Loading
Nanoparticle-based Drug Delivery / RNA Interference and Gene Delivery / Nanoplatforms for Cancer Theranostics · Journal article
Journal of Visualized Experiments · August 14, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a methods protocol presenting fabrication and characterization of light- and X-ray-triggered liposomes for controlled release of gene-editing and chemotherapy payloads. Representative results in zebrafish and mouse models show proof-of-concept, but clinical safety, pharmacokinetics, and biodistribution remain uncharacterized and would be required before any clinical translation.
Methods protocol with in vitro and in vivo proof-of-concept validation. In vitro: human cells for gene knockout assay. In vivo: zebrafish embryos (visual reporter system) and mice bearing xenograft tumours. No human subjects.. Intervention: Light-triggered liposomes (690 nm visible light activation) and X-ray-triggered liposomes (6 MeV clinical X-ray radiation) containing verteporfin for on-demand cargo release..
Light-triggered liposomes achieved knockout of approximately 326 slow-muscle fibres per zebrafish embryo via 690 nm activation X-ray-triggered liposomes (6 MeV) demonstrated significant tumour growth suppression via doxorubicin release in mouse xenograft model Verteporfin generates singlet oxygen upon 690 nm or X-ray activation, destabilising lipid membrane and releasing cargo
Clinical applicability stated as requiring establishment of retinal biodistribution, pharmacokinetics, and large-animal safety.
This work presents a platform approach with translational potential for spatiotemporally controlled therapeutic delivery. However, the authors explicitly identify critical gaps—retinal biodistribution, pharmacokinetics, and large-animal safety—that must be closed before any clinical evaluation in ophthalmology or oncology can proceed.
Early-phase methodology paper demonstrating proof-of-concept for light- and X-ray-triggered liposomes in preclinical models without clinical efficacy or safety data.
As stated by the source record.
Quoted from the source exactly as published.
This work presents a platform approach with translational potential for spatiotemporally controlled therapeutic delivery. However, the authors explicitly identify critical gaps—retinal biodistribution, pharmacokinetics, and large-animal safety—that must be closed before any clinical evaluation in ophthalmology or oncology can proceed.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Photodynamic therapy (PDT) exploits photosensitizer activation to generate reactive oxygen species (ROS), principally singlet oxygen. Beyond direct cytotoxicity, this photochemistry can be repurposed for on-demand cargo release from lipid nanocarrier systems, enabling spatiotemporal control over therapeutic delivery that is not achievable with conventional lipid nanoparticles. This protocol presents methods for fabricating and characterising two distinct verteporfin (VP)-integrated lipid nanoparticle formulations: (1) light-triggered liposomes composed of DOTAP, DOPE, cholesterol, and VP for delivery of CRISPR-Cas9 ribonucleoprotein (RNP) complexes; and (2) X-ray-triggered liposomes composed of DOTAP, DOPC, VP, and gold nanoparticles for controlled chemotherapy drug release. Upon activation at 690 nm (visible light) or by clinical X-ray radiation (6 MeV), VP generates singlet oxygen that oxidises unsaturated lipid components, destabilising the nanoparticle membrane and releasing encapsulated cargos. Protocols are provided for liposome formulation by thin-film hydration and membrane extrusion, physicochemical characterisation, light- and X-ray-triggered cargo release assessment, in vitro gene knockout in human cells, and in vivo validation using a quantitative zebrafish visual reporter system and a mouse xenograft tumour model. Representative results demonstrate knockout of up to approximately 326 slow-muscle fibres per zebrafish embryo via light activation and significant tumour growth suppression via X-ray-triggered doxorubicin release.The clinical precedent for 689-690 nm verteporfin activation in the eye motivates evaluation of this platform for ophthalmic delivery, although retinal biodistribution, pharmacokinetics, and large-animal safety remain to be established. These methods provide an experimental approach with translational potential for externally controlled therapeutic cargo release.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.